Duncker Streett & Co. Inc. Lowers Position in Pfizer Inc. (NYSE:PFE)

Duncker Streett & Co. Inc. cut its holdings in Pfizer Inc. (NYSE:PFE) by 26.5% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 28,201 shares of the biopharmaceutical company’s stock after selling 10,159 shares during the quarter. Duncker Streett & Co. Inc.’s holdings in Pfizer were worth $748,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC bought a new position in Pfizer in the fourth quarter worth about $26,000. Gladius Capital Management LP raised its holdings in Pfizer by 102.8% in the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 38,015 shares in the last quarter. Noble Wealth Management PBC bought a new position in Pfizer in the fourth quarter worth about $31,000. Sierra Ocean LLC acquired a new position in shares of Pfizer during the fourth quarter valued at about $34,000. Finally, Teachers Insurance & Annuity Association of America acquired a new position in shares of Pfizer during the third quarter valued at about $35,000. 68.36% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Pfizer news, Director Ronald E. Blaylock bought 19,457 shares of the firm’s stock in a transaction dated Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares of the company’s stock, valued at approximately $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.06% of the company’s stock.

Pfizer Trading Up 1.3 %

Shares of NYSE:PFE opened at $26.43 on Friday. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The firm has a market capitalization of $149.78 billion, a price-to-earnings ratio of 18.74, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business’s 50 day moving average price is $26.35 and its 200-day moving average price is $27.33.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The firm had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same quarter last year, the firm posted $0.10 EPS. The business’s revenue was up 24.7% on a year-over-year basis. On average, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a dividend of $0.43 per share. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.51%. Pfizer’s dividend payout ratio (DPR) is 121.99%.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on PFE. Citigroup cut their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating on the stock in a report on Tuesday, January 28th. Bank of America restated a “neutral” rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. Wolfe Research initiated coverage on shares of Pfizer in a report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price target on the stock. StockNews.com downgraded shares of Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Finally, Guggenheim reiterated a “buy” rating and issued a $33.00 price target on shares of Pfizer in a report on Monday, February 10th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Pfizer presently has an average rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.